drugset / Trial / NCT00004278
Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection
Phase 3
Completed
130 enrolled
National Center for Research Resources (NCRR)
National Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedTreatment
Summary
OBJECTIVES: I. Evaluate the efficacy of ganciclovir (12 mg/kg per day) versus no treatment in neonates with symptomatic congenital cytomegalovirus infection with central nervous system disease.
Timeline
- Start
- 1991-12
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ganciclovir | Small molecule | 12 mg/kg | Intravenous |